博瑞医药
(688166)
| 流通市值：111.74亿 | | | 总市值：111.74亿 |
| 流通股本：4.22亿 | | | 总股本：4.22亿 |
| 报告期 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 914,877,843.44 | 587,482,000.41 | 304,937,396.25 | 1,017,331,488.33 |
| 营业收入 | 914,877,843.44 | 587,482,000.41 | 304,937,396.25 | 1,017,331,488.33 |
| 二、营业总成本 | 699,599,219.95 | 462,934,616.31 | 229,202,715.92 | 783,330,526.79 |
| 营业成本 | 378,939,159.77 | 258,342,655.65 | 125,394,155.39 | 376,298,728.3 |
| 税金及附加 | 4,420,583.31 | 2,866,941.96 | 1,394,873.41 | 5,223,457.4 |
| 销售费用 | 45,103,971.42 | 28,416,081.01 | 16,556,510.14 | 70,093,663.14 |
| 管理费用 | 83,108,544.28 | 51,811,316.04 | 28,280,327.1 | 114,889,970.48 |
| 研发费用 | 163,815,024.16 | 103,387,808.27 | 48,657,672.09 | 207,024,938.02 |
| 财务费用 | 24,211,937.01 | 18,109,813.38 | 8,919,177.79 | 9,799,769.45 |
| 其中:利息费用 | 33,568,259.32 | 23,936,837.91 | 10,691,270.02 | 23,710,367.55 |
| 其中:利息收入 | 10,398,097.47 | 7,445,851.53 | 2,987,243.42 | 2,238,776.92 |
| 加:公允价值变动收益 | 255,430.6 | 1,742,476.26 | 334,714.5 | -3,394,640.81 |
| 加:投资收益 | -8,237,797.91 | -4,806,517.77 | -1,552,441.38 | 3,956,915.37 |
| 资产处置收益 | - | - | - | 9,885.9 |
| 资产减值损失(新) | -8,112,220.14 | -8,112,220.14 | - | -14,648,770.22 |
| 信用减值损失(新) | -6,882,150.46 | -3,778,681.59 | 250,038.08 | 1,373,032.43 |
| 其他收益 | 5,654,571.7 | 3,951,184.02 | 838,629.26 | 20,857,831.31 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 197,956,457.28 | 113,543,624.88 | 75,605,620.79 | 242,155,215.52 |
| 加:营业外收入 | 194,609.59 | 11,370.1 | 1.76 | 1,051,016.49 |
| 减:营业外支出 | 462,778.35 | 278,413.25 | - | 999,010.76 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 197,688,288.52 | 113,276,581.73 | 75,605,622.55 | 242,207,221.25 |
| 减:所得税费用 | 20,947,593.65 | 14,887,037.49 | 9,561,010.79 | 30,780,264.65 |
| 六、净利润 | 176,740,694.87 | 98,389,544.24 | 66,044,611.76 | 211,426,956.6 |
| 持续经营净利润 | 176,740,694.87 | 98,389,544.24 | 66,044,611.76 | 211,426,956.6 |
| 归属于母公司股东的净利润 | 191,790,741.75 | 109,440,368.55 | 70,769,470.45 | 239,623,172.71 |
| 少数股东损益 | -15,050,046.88 | -11,050,824.31 | -4,724,858.69 | -28,196,216.11 |
| (一)基本每股收益 | 0.45 | 0.26 | 0.17 | 0.58 |
| (二)稀释每股收益 | 0.45 | 0.26 | 0.17 | 0.58 |
| 八、其他综合收益 | -4,907,097.88 | -4,055,484.67 | - | -34,204,518.87 |
| 归属于母公司股东的其他综合收益 | -4,907,097.88 | -4,055,484.67 | - | -34,204,518.87 |
| 九、综合收益总额 | 171,833,596.99 | 94,334,059.57 | 66,044,611.76 | 177,222,437.73 |
| 归属于母公司股东的综合收益总额 | 186,883,643.87 | 105,384,883.88 | 70,769,470.45 | 205,418,653.84 |
| 归属于少数股东的综合收益总额 | -15,050,046.88 | -11,050,824.31 | -4,724,858.69 | -28,196,216.11 |
| 公告日期 | 2023-10-27 | 2023-08-25 | 2023-04-25 | 2023-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |